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in the main outcome measure, at a 5% significance level. The patients were identified by their GPs and were then referred to the trial office. Of an estimated 2,000 potentially eligible patients, 201 agreed to participate. There were 109 patients in the control group and 92 in the intervention group. The demographics of the patients were not reported.
Study design
This was a prospective, randomised controlled trial, which was carried out by 54 GPs in 14 practices in Northwest Wales. Randomisation was stratified according to symptom location, the referring GPs' perception of symptom severity, and whether the pain was a first episode or a recurrence. The basis of the method was random number tables kept secure from all participants. The unit of randomisation was the patient. The length of follow-up was 6 months, although the outcomes were also assessed after 2 months. At the final assessment, medical data were available for 101 control patients (93%) and for 86 intervention patients (95%). However, the 6-month questionnaire return rate was 66% in the control group and 70% in the intervention group. The assessment was not carried out blind.
Analysis of effectiveness
The analysis of the clinical study was conducted on an intention to treat basis. The primary health outcome was the Extended Aberdeen Spine Pain Scale (EASPS), which comprised several condition-specific measures for spinal pain and disability. The secondary health outcome measures were the Short-form McGill Pain Questionnaire (SMPQ), the SF-12 health profile, and the EuroQol (EQ-5D) index of health utility. The authors stated that, at baseline, the study groups were comparable in terms of their sociodemographic characteristics, baseline outcome scores, or treatment activity and health service costs.
Effectiveness results
At 2 months, the mean change in the EASPS score was 8.6 (+/-14.2) in the control group and 13.9 (+/-12.8) in the intervention group. The difference was 5.3 (95% confidence interval, CI: 0.7 -9.8; p=0.02).
Although both groups reported improvements, no statistically significant differences were generally observed in the SMPQ, EQ-5D and SF-12 scores. The exception was the SF-12 mental score, which was significantly better in the intervention group.
No adverse events were observed.
At 6 months, only the SF-12 mental score was significantly better in the intervention group, 1.14 (+/-11.3) versus 6.8 (+/-13.6) in the control group. The difference was 5.5 (95% CI: 1 -9.9; p=0.02).
Clinical conclusions
The effectiveness analysis showed that the osteopathy service improved both short-term physical outcomes and longterm psychological outcomes.
Measure of benefits used in the economic analysis
The health outcomes were left disaggregated and no summary benefit measure was used in the economic analysis. The authors stated that a cost-consequences analysis was conducted.
Direct costs
Discounting was not relevant because the costs were incurred during less than 2 years. The unit costs and the quantities of resources used were presented separately. The health services included in the economic evaluation were primary care consultations, investigations, prescribing and referrals. The cost/resource boundary of the NHS was adopted. Resource use was estimated from actual individualised data, which were derived from the sample of patients involved in the effectiveness study. Data were estimated for the 6 months before and 6 months after randomisation. The costs were estimated from national sources and 1999/2000 prices were used.
